This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

VK5211

Viking Therapeutics, Inc.

Drug Names(s): LGD-4033, VK 5211, VK-5211

Description: LGD-4033 is a next-generation selective androgen receptor modulator (SARM) designed to provide the benefits of androgen receptor stimulation on skeletal muscle and bone without the side effects of currently marketed androgens. SARMs are designed to elicit the desired biological effects without the undesirable side effects or potential risks over time of currently marketed androgens, providing a wide range of opportunities for the treatment of many diseases and disorders in both men and women. Tissue-selective androgen receptor agonists may provide utility in the treatment of a number of medical conditions, including frailty, cachexia, osteoporosis, sexual dysfunction and hypogonadism. Ligand has discovered orally active, non-steroidal SARM compounds, such as LGD-4033, based on tissue-specific gene expression and other functional, cell-based technologies.

Deal Structure: Ligand and Viking
In May 2014, Ligand announced the licensing of rights to five programs to Viking Therapeutics. The therapeutic programs covered in the license agreement include Ligand's FBPase inhibitor program for type 2 diabetes, a Selective Androgen Receptor Modulator (SARM) program for muscle wasting, a Thyroid Hormone Receptor- (TR) Agonist program for dyslipidemia, an Erythropoietin Receptor (EPOR) Agonist program for anemia, and an Enterocyte-Directed Diacylglycerol Acyltransferase-1 (DGAT-1) Inhibitor program for dyslipidemia. The FBPase Inhibitor program was the subject of an option originally granted to Viking in 2012.

Each licensed program includes a fee to be paid to Ligand in Viking equity at the time of a private or public financing, milestone payments and royalties on future net sales. Viking is responsible for all development activities under the license. As part of this transaction, Ligand has agreed to extend a $2.5 million convertible loan...See full deal structure in Biomedtracker

Partners: Ligand Pharmaceuticals, Inc.


VK5211 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug